Category Archives: Stem Cell Medicine


Honor for pioneering equine stem cell researcher – Horsetalk

An equine cartilage disk, of about 4mm in diameter, is being used in trials in Canada, thanks to stem cell researcher Dr Thomas Koch.

An equine stem cell researcher is among theinaugural recipients of new University of Guelph internal awards recognizing research excellence and innovation.

Dr Thomas Koch, from Ontario Veterinary Colleges Department of Biomedical Sciences, has received a Research Excellence Award.

The awards recognize both researchers who are embarking on stellar careers and those whose research successes already set them apart from their colleagues in their disciplines globally, said University of Guelphvice-president (research) Malcolm Campbell.

Koch, who was recently recognized with a 2016 Early Researcher Award from the Ontario Ministry of Research and Innovation, focuses his research on stem cell biology, tissue engineering-based therapies and regenerative medicine. In particular he is studying the potential of stem cells to repair damage to joints and cartilage. His work on equine stem cells for cartilage repair includes finding better ways to treat horses, as well as using the horse as a model for testing new therapies for humans. Koch is also a founding member and current vice-chair of the North American Veterinary Regenerative Medicine Association.

In 2012, Koch isolated mesenchymal stromal cells (MSCs) for potential cartilage repair using a simple, non-invasive procedure.

He was recognised along with DrShayan Sharif, a professor of poultry immunology at the OVCs Department of Pathobiology, who received a Research Leadership Chair.

Drs Sharif and Koch are among our best: they were nominated by their peers, not only because of their outstanding scholarly accomplishments, but also because they are exemplary citizens of the University of Guelph, said OVC Dean Jeff Wichtel.

The Chair and the Award are well-deserved acknowledgements of their continued commitment to research excellence in their respective disciplines, and highlight once again OVCs strengths in translational medicine, food animal production, food safety and security.

Created by the U of Gs Office of Research and the Office of the Provost, the awards will be made annually.

Research Excellence awards are a one-time, $5000 award. Early career faculty who are one to two years post-tenure are eligible. Research Leadership Chairs are for well-established faculty who have demonstrated research excellence. The $15,000 awards are for three years, with a possible extension to five years.

Award winners will present their work to U of G and the wider Guelph community through special research events. Each of U of Gs seven colleges will be eligible for one Research Excellence Award recipient and up to two Research Leadership Chairs. Recipients are nominated and selected by their respective colleges. Awards are based on scholarly output, research-related knowledge mobilization, research-derived innovation and training of highly qualified personnel.

Visit link:
Honor for pioneering equine stem cell researcher - Horsetalk

Speculator makes case for candidates to end years of hurt for stem cell investors – The Pharma Letter (registration)

Most early stage stem cell investors have lost their shirts, admits a market commentator as it puts forward

To continue reading this article and to access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space you need to be logged into the site and have an active subscription or trial subscription. Please loginorsubscribe in order to continue reading. Claim a week's trial subscriptionby signing up for free today and receive our daily pharma and biotech news bulletin free of charge, forever.

BiotechnologyGeneticsResearchStem Cell Therapy

Access The Pharma Letter's latest news free for 7 days

PLUS... you can receive the Pharma Letter headlines and news roundup email free forever

Click here to take a free trial

Unlimited access to The Pharma Letter site for a whole year Only 77 per month or 820 per year

Click here to subscribe

View original post here:
Speculator makes case for candidates to end years of hurt for stem cell investors - The Pharma Letter (registration)

The Big Deal About Stem Cell Therapies and Regenerative Medicine – PR Newswire UK (press release)

However, when looking at this great promise in terms of return on investment, let us be completely honest, most early stage stem cell investors have lost their shirts. We are now more than twenty years removed from the earliest commercial stem cell companies that were founded in the late 1980's, went public in the late 1990's and who were once seen as an exciting investment opportunity, but ended up being a huge disappointment.

So, should investors still be interested in regenerative medicine? After all, stem cells have largely produced failures and unregulated stem cell clinics marketing unproven therapies are taking over. The answer is a resounding yes, but the dot-com like era of regenerative medicine, which led investors to pour money into anything and anyone marketing a cell therapy is over. Investors will need to look at companies solving issues with stem cells or those taking a completely new approach.

One company that is looking to address many of the issues with stem cell therapies, as well as developing another approach to regenerative medicine is Endonovo Therapeutics, Inc. (OTCQB: ENDV). On the stem cell front, ENDV is using its Time Varying Electromagnetic Fields (TVEMF) technology, originally developed at the National Aeronautics and Space Administration (NASA) to expand and activate stem cells to produce more biologically potent cell therapies. However, more importantly, ENDV is developing a non-invasive medical device that would render many of the cell therapies currently under development obsolete. These devices, called Electroceuticals, harness the electrical signals that our cells and nerves use to control the immune and regenerative response to treat inflammatory and degenerative diseases. ENDV is developing this exciting technology for treating and preventing heart failure following a heart attack, to treat chronic kidney disease, peripheral artery disease and non-alcoholic steatohepatitis (NASH).

Another small biotech company like ENDV working on electric treatments for diseases is Pulse Biosciences (NASDAQ: PLSE), whose Nano-Pulse Stimulation (NPS) technology uses nano second electric pulses to illicit an immune response for the treatment of cancer. PLSE recently announced the treatment of its first patient in a study to evaluate the safety and efficacy of its novel NPS technology for seborrheic keratosis (SK) lesions. SK is one of the most common types of skin lesions, affecting more than 80 million patients in the United States. Additionally, PLSE announced that it will host its quarterly investor conference call on July 27, 2017, at 1:30 p.m. PDT / 4:30 p.m. EDT. The company will provide an update on the clinical advancement of the PulseTx[TM] System, including progress of the clinical study evaluating NPS for the treatment of seborrheic keratosis (SK), as well as the status of the 510(k) submission from earlier this year.

Another company seeking to address past pitfalls of stem cell therapies is Pluristem Therapeutics, Inc. (NASDAQ: PSTI) is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. Pluristem's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. This process allows the cells to be expanded rapidly while remaining healthy and potent cells that can secrete therapeutic biomolecules. The Company's PLX products are administered using a standard needle and syringe. PSTI recently announced that Austria's regulatory health agency, the Austrian Agency for Health and Food Safety (AGES), had cleared Pluristem to begin enrollment in Austria for its pivotal Phase III trial of PLX-PAD cells to treat critical limb ischemia.

In other stem cell news:

Cytori Therapeutics, Inc. (NASDAQ: CYTX) recently announced that its STAR study assessing its Habeo Cell Therapy for the treatment of Scleroderma had failed to meet its primary endpoint at week 24 nor any of its secondary endpoints at week 24 or week 48. On the other hand, CYTX stated that there were 'clinically meaningful' improvements in both the primary and secondary endpoints of both hand function and scleroderma-associated functional disability compared to placebo in a subgroup of patients with diffuse cutaneous scleroderma, a more severe form of the disease. The company has stated that it will continue it analysis of the data before determining its next steps.

Capricor Therapeutics, Inc. (NASDAQ: CAPR) a biotechnology company developing biological therapies for Duchenne muscular dystrophy and other rare diseases, following news that Janssen Biotech, Inc. had decided not to exercise its option to exclusively license Capricor's lead candidate CAP-1002 for the development and commercialization in the field of cardiology, announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to CAP-1002, Capricor's development candidate for the treatment of Duchenne muscular dystrophy, a debilitating genetic disorder characterized by progressive weakness and chronic inflammation of skeletal, heart, and respiratory muscles. The Rare Pediatric Disease Designation, as well as the Orphan Drug Designation previously granted to CAP-1002 by the FDA, covers the broad treatment of DMD. Upon receiving market approval for CAP-1002 by the FDA, Capricor would be eligible to receive a Priority Review Voucher.

Microcap Speculators

Email: info@microcapspecualtors.com

Phone: +1-702-720-6310

Website: http://microcapspeculators.com/

DISCLAIMER: Microcap Speculators (MS) is the source of the content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with MS or any company mentioned herein. The commentary, views and opinions expressed in this release by MS are solely those of MS and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable MS and FNM for any investment decisions by their readers or subscribers. MS and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.

MS Disclosure: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC. which owns Microcapspeculators.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC. which owns, Microcapspeculators.com may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC. which owns Microcapspeculators.com may be compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. For Full Legal Disclaimer Please use this link:http://microcapspeculators.com/disclaimer/

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MS and FNM undertake no obligation to update such statements.

Media Contact FN Media Group, LLC editor@financialnewsmedia.com +1-(954)345-0611

SOURCE Microcapspeculators.com

Read the original here:
The Big Deal About Stem Cell Therapies and Regenerative Medicine - PR Newswire UK (press release)

Dozens of US clinics sell unproven stem cell therapies for heart failure – Reuters

(Reuters Health) - Stem cell therapy isnt approved to treat heart failure in the U.S., but dozens of clinics nationwide advertise the treatments anyway, often charging thousands of dollars for procedures that may not be safe or effective, a new study suggests.

Researchers found 61 centers offering stem cell therapies for heart failure as of last year in the U.S. alone, including five that claimed to have performed more than 100 procedures. Only nine centers required copies of patients medical records and just one facility said it had a board certified cardiologist on staff.

We simply do not know anything about the quality of the treatment delivered at these centers, said senior study author Dr. Paul Hauptman director of heart failure at Saint Louis University Hospital.

These centers are not regulated in any way, Hauptman said by email.

Almost 6 million Americans have heart failure, and its one of the most common reasons older adults go to the hospital, according to the American Heart Association.

It happens when the heart muscle is too weak to effectively pump enough blood through the body. Symptoms can include fatigue, weight gain from fluid retention, shortness of breath and coughing or wheezing. Medications can help strengthen the heart and minimize fluid buildup in the body.

While some experimental stem cell therapies for heart failure are currently being tested in late-stage human trials, none have won approval from the U.S. Food and Drug Administration.

In theory, after a transplant, stem cells could permanently become part of the diseased heart and either help grow new healthy heart tissue or tell existing cells to work better, said Paul Knoepfler, a cell biology researcher at the University of California Davis School of Medicine in Sacramento who wasnt involved in the study.

Its also possible stem cells could temporarily visit the heart and stimulate a positive response in cells already there, he said.

Even though theres no conclusive proof yet that any stem cell treatments are safe and effective for heart failure, centers contacted for the study charge an average of $7,694 for each treatment using patients own stem cells and $6,038 for each procedure with donor stem cells.

In one instance, though, a clinic staff member said, If you have a million dollars to spend we will set you up with weekly infusions.

Hauptmans team had used a standard script when contacting each center, asking about the stem cell treatment itself, medical exams before and afterward and pricing.

Among the other responses they received from clinic staff were remarks such as, If you know anyone that can start an IV, a neighbor that is a nurse for example, we can send you the stem cells and that person can administer them to you and We hope you don't believe your doctor when they tell you there is nothing they can do, you were smart to call us.

None of the sites in the study discussed what methods they used to isolate or identify stem cells, though most claimed to use patients cells and 24 said they got cells from fat tissue.

Most centers claimed to deliver cells intravenously, researchers report in JAMA Internal Medicine.

This approach has been associated with complications such as stroke, in which infused cells block blood vessels in the brain, said Douglas Sipp, a researcher at RIKEN Center for Developmental Biology in Kobe, Japan, who wasnt involved in the study.

The biggest risk is that patients will waste their money, time and hopes on an unnecessary and useless invasive procedure, Sipp said by email.

If any stem cell treatment did ultimately prove safe and effective enough to win FDA approval, it would likely offer a significant improvement over the limited treatment options currently available, said Leigh Turner, a researcher at the University of Minnesota Center for Bioethics who wasnt involved in the study.

But its impossible to say what patients would get at unregulated clinics offering unapproved stem cell therapies, Turner said by email. In at least two cases unrelated to the current study, patients died after getting stem cell procedures at a clinic in Florida, and in another case at a different Florida clinic, a woman went blind, Turner noted.

Clinics marketing stem cell treatments to patients suffering from heart failure might be administering anything from slurries of mixed cells, some of which might be stem cells, to nothing more than cellular debris, Turner said. Often one can only speculate.

SOURCE: bit.ly/2uQve40 JAMA Internal Medicine, online July 24, 2017.

Visit link:
Dozens of US clinics sell unproven stem cell therapies for heart failure - Reuters

Regenexx Announces Successful Merger with Harbor View Medical – OrthoSpineNews

Share this story with your network

BROOMFIELD, Colo.(BUSINESS WIRE)Regenexx, a Colorado-based stem-cell-treatment network and pioneer in the invention of interventional orthopedics, today announced that it successfully merged withHarbor View Medical, a leader in orthopedic stem cell therapy and part of the Regenexx network, which became effective in May 2017. As part of the transition, Jason Hellickson has assumed the CEO role. This merger positions Regenexx to further expand its National Network to better serve patients and our corporate partners.

Regenexx Corporate will be headquartered in Des Moines, IA, while Regenexxs Affiliate Program and Research and Development will be lead out of the companys Broomfield, CO location. Dr. Christopher Centeno, founder of orthopedic stem cell treatments and leader of interventional orthopedics in the United States and pioneer of the Regenexx patented procedures, will continue his role as Chief Medical Officer and remain in clinic operations in Broomfield, and continues the advancements of regenerative medicine through the largest research and data collection effort in orthopedic regenerative medicine.

As the most advanced non-surgical orthopedic care available in the United States, Im excited to continue our mission to producing the best possible patient outcomes through interventional orthopedics, said Jason Hellickson, CEO, Regenexx. In addition to individual personalized care, we will continue to provide both employers and their employees with cost savings results and successful interventions to orthopedic surgery.

Since joining the Regenexx Network in late 2014, Hellickson has reengineered clinic operations which increased capacity by more than 300 percent while offering a streamlined approach beneficial to both patients and clinic staff. He is the innovator and leader of theRegenexx Corporate Programthat enables large employers access to the Regenexx procedures. Since adding Regenexx procedures to their self-funded health and workers compensation plans, corporate partners have saved as much as 83 percent in their orthopedic surgical expenses, totaling in the many millions of dollars. In his new role, Hellickson will continue to architect the Regenexx national clinical operations to create more streamlined approaches to patient care and expand Regenexx clinics nationwide.

We look forward to continuing the build-out of Regenexx clinics, streamlining affiliate networks of more than 50 clinics nationwide, and adding additional clinics in major metropolitan areas including Chicago, Atlanta, Dallas, Philadelphia, and Charlotte under Jasons helm, said Christopher Centeno, MD. Were excited about the experience and enthusiasm that Jason brings to Regenexx.

Regenexx is the world leader in interventional orthopedics using orthobiologics and has been issued many patents for its evidence-based stem cell and blood platelet treatments used for back pain, joint pain, arthritis and acute orthopedic injuries. The benefits of interventional orthopedics are so revolutionary that seventy percent of orthopedic issues currently treated with surgery could instead be handled using regenerative methods. Mesenchymal stem cells are multipotent, adult stem cells that are therapeutic agents in the repair and regeneration of muscle, tissue, cartilage and bone. Regenexx procedures use a patients own bone marrow-derived stem cells, or blood platelets, through a blood draw, to customize needle-based, precisely-guided procedures to treat common orthopedic conditions. Its procedures have been proven to have the same or better outcomes compared to their surgical alternative.

For more information on the Regenexx Corporate Program call: 888-547-6667. For general information on Regenexx, please visitwww.Regenexxcorporate.com. For a map of current Regenexx clinics and providers clickhere.

About Regenexx and the Regenexx Physician Network The Regenexx Procedures are the nations most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patients own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.

For more information on Regenexx, please visit:http://www.regenexx.com

Read the original post:
Regenexx Announces Successful Merger with Harbor View Medical - OrthoSpineNews

Stem Cells Guided by Electric Fields May Offer New Therapies for … – Genetic Engineering & Biotechnology News (press release)

Scientists at the University of California, Davis School of Medicine's Institute for Regenerative Cures report that electric fields can be used to guide neural stem cells transplanted into the brain toward a specific location. Their study (Electrical Guidance of Human Stem Cells in the Rat Brain), which appears in Stem Cell Reports, opens the door for potentially guiding stem cells to repair brain damage.

we report a strategy that mobilizes and guides migration of stem cells in the brain invivo. We developed a safe stimulation paradigm to deliver directional currents in the brain, write the investigators. Tracking cells expressing GFP [green fluorescent protein] demonstrated electrical mobilization and guidance of migration of human neural stem cells, even against co-existing intrinsic cues in the rostral migration stream.

Min Zhao, M.D., Ph.D., carries out research on how electric fields can guide wound healing. Damaged tissues generate weak electric fields, and Zhao's research has shown how these electric fields can attract cells into wounds to heal them.

"One unmet need in regenerative medicine is how to effectively and safely mobilize and guide stem cells to migrate to lesion sites for repair," Dr. Zhao said. "Inefficient migration of those cells to lesions is a significant roadblock to developing effective clinical applications."

Natural neural stem cells are found deep in the brain, in the subventricular zone and hippocampus. To repair damage to the cortex, they have to migrate some distance, especially in the large human brain. Transplanted stem cells might also have to migrate some way to find an area of damage.

Dr. Zhao, and his colleague, Junfeng Feng, M.D., a neurosurgeon at Ren Ji Hospital, Shanghai Jiao Tong University, and Shanghai Institute of Head Trauma, developed a model of stem cell transplants in rats. They placed human neural stem cells in the rostral migration stream, which is a pathway in the rat brain that carries cells toward the olfactory bulb. Cells move along this pathway, partly carried by the flow of cerebrospinal fluid and partly guided by chemical signals.

By applying an electric field within the rat's brain, the scientists found that they could get the transplanted stem cells to swim upstream against the fluid flow and natural cues and head for other locations within the brain.

The transplanted stem cells were still in their new locations weeks or months after treatment.

"Electrical mobilization and guidance of stem cells in the brain therefore provides a potential approach to facilitate stem cell therapies for brain diseases, stroke, and injuries," noted Dr. Zhao.

Read the original:
Stem Cells Guided by Electric Fields May Offer New Therapies for ... - Genetic Engineering & Biotechnology News (press release)

Danvers health group offers alternative solution to surgery – Wicked Local North of Boston

Stem cell therapy: the next wave in regenerative medicine?

All it involved was a quick injection no different, really, than a flu shot.

A few weeks later, Bill Ambrose realized hed become significantly less reliant on taking Aleve for knee pain, and he was re-learning how to walk without shuffling his feet.

Surgery, it turned out, might not be necessary after all.

Last November, Ambrose scheduled knee surgery to alleviate discomfort in his knees caused by what orthopedic doctors called true bone-on-bone at the joint. But for one reason or another, he kept missing pre-surgery and the surgery never happened.

The next month, Ambrose met with Dr. Bill Nolan, of Cherry Street Health Group, to discuss advertising space in the Danvers Herald.

For the purpose of full disclosure, Ambrose is an employee of Gatehouse Media Company, and he works in the advertising department for Wicked Local, the local branch of GHM newspapers.

After Nolans ads ran inthe Jan. 5issue of the Herald, Ambrose said he reached out to Nolan again. This time, for himself.

Nolans practice offered a solution to his knee pain an alternative to knee surgery he had never considered before: stem cell therapy.

Essentially, the solutionCherry StreetHealth Group offered was an injection of amniotic fluid into Ambrose's knee joint. The stem cells and other growth factorsin the fluid would allow for the regeneration of the cartilage at the joint.

I became interested so I decided to go ahead with it, Ambrose said.

He brought in scans to show Nolan, who said, contrary to what orthopedic doctors had told him, he didnt have true bone on bone. There was still a small space between the bones.

I decided to have one leg done and my knee started getting much better, he said.

Satisfied with the results of the first injection, Ambrose decided to get his left knee done in April.

I still experience some pain in [the left knee], but I get up in the morning and theres very little pain at all, he said in an interview a few weeks following the appointment.

The stem cell option

In the U.S., there are three ways that stem cells are used, Nolan said. Theyre either taken from bone marrow, fat cells, or the amniotic membrane of a healthy c-section from a consenting woman.

When stem cellsare injected into the body,they're expected to increase space at the joint, rebuild cartilage, and ultimately, provide more stability in the joint. As many as 570 businesses across the country advertise some kind of stem cell therapy, according to a 2016 paper.

Stem cell therapy is not necessarily a new discovery, but it is relatively recent in the world of regenerative medicine.Stem cells were first used as much as century ago, first for eye procedures and as filler for the spinal cord, according to Regenexx, which claims to have pioneered orthopedic stem cell treatments in 2005.

Adult stem cells are retrieved directly from the patient, either frombone marrow or fat cells,and concentrated beforeits reinjectedinto the patient's site of pain.

In the case of amniotic fluid therapy,amniotic fluid, which contains stem cells and other growth factors, is injected into the site. These cellshave been shown to "expand extensively" and show "high renewal capacity,"according to research published in the National Library of Medicine.

We know that as you age, your stem cell count decreases,Nolan said, explaining the benefit of using cells from the amniotic membrane. We know that when we get it from the amniotic membrane, theres a large amount of stem cells that are present. From the amniotic membrane, there are no antibodies or antigens, so its safe for anyone to get.

At Cherry Street Health Group, theproduct usedis produced by General Surgical and distributed by RegenOMedix, according to Nolan.The product, which is called ReGen Anu RHEO, is American Tissue Bank approved and FDA cleared.

RHEO is marketed as "a human tissue allograft derived from placental tissue; amniotic membrane and amniotic fluid."Its a"powerful combination" of amniotic fluid and mesencymal stem cells, which are known to differentiate into a variety of cell types, according to RegenOMedix.It also contains growth factor proteins andis "rich" in other necessary components for tissue regeneration.

The product is non-steroidal and comes with no side effects, and the company says no adverse events have been recorded using the product.

Nolan said stem cell therapy has been offered as a treatmentat Cherry Street since 2016.

Across the U.S., there are as many as 56 businesses marketing some form of amniotic stem cellsto its consumers, according to the same paper.

At Rush University Medical Center in Chicago, for example, orthopedic surgeon Adam Yanke enrolled one of his patients into an experimental amniotic cell therapy treatment program. The woman, a 65-year-old suffering from osteoarthritis in both knees, told reporters the injections were "by far the most effective pain treatment" she had tried, and so farthat relief has lasted up to a year.

But while the use of amniotic fluid therapyas a regenerative medicine is becoming increasingly popular throughout the U.S.,the use of amniotic stemcellsdoesn't comewithout concern from some within the community.

Dr. Chris Centeno, who specializes in regenerative medicine andthe clinical use of adult stem cells, has blogged numerous times for Regenexx on the "scam" of using amniotic stem cells most recently in sharply worded post on May 22.

"Regrettably, we have an epidemic on our hands that began when sales reps began telling medical providers thattheir dead amniotic and cord tissues had loads of live cells on it," he wrote.

Nolan said he was familiar with Centeno's posts.

"A lot of the stem cell stuff is new," he said. "Some of the products out there ... They were doing testing on them and not finding cells."

Cherry Street Health Group has treatedabout 50patients with this form of regenerative medicine and had significant success, according to Nolan. Although Nolan owns the health group on Cherry Street in Danvers, the stem cell treatments are provided under the medical practice of Dr. Pat Scanlan.

Weve had really, really amazing success, Nolan said. Weve had over 95 percent success of all the patients weve had in the office. Its been a game changer from a practice standpoint.

The "worst thing" that could happen is there might not be any regeneration, he explained.

"You might get pain relief, but no regeneration," Nolan said. "But from what weve seen, there have been no negative side effects."

At Cherry Street, knees are the most commonly treated joints, followed by hips, shoulders and the lower back. The cervical spine is the least common.

"I hesitated on the surgery, and I'm gladI did," Ambrose said. "Even if[the stem cells]don't do any more than what they've done, its been well worth it."

Patients who do present with true bone on bone, however, are not candidates for this form of therapy, Nolan said.

The cost comparison

At Cherry Street Health Group, the cost of the injection comes toroughly $4,000 per knee, a cost that isn't covered by insurance. By comparison, health-care providers often charge insurers more than $18,000 for knee replacement surgeries in the Boston area, according to a report by the Blue Cross and Blue Shield Association.

The report, however, doesn't account for what the patient actually pays.

Nolan said when other factors of post-op are considered time off of work, rehabilitation time and cost the out-of-pocketcost for surgery compared to stem cell treatment is comparable.

"When you really boil it down, it can be the same or, in a lot of cases, a savings," he said.

Ambrose said it "boggles his mind" that more people don't choose this treatment over surgery.

"Why would you spend $40,000 on a car and not want to spend $4,000 on a knee?," he said."Its crazy. Yes, its out of pocket. So what? We buy a lot of stuff we dont need, and then for something like this, something that people, if they do it, theyll be glad they did it. Its just hard to convince them to do it."

In arecent report in STAT news, a health news start up of the Boston Globe, a study of orthopedic procedures in the U.S. suggested an estimated one-third of knee replacement surgeries are inappropriate. More than 640,000 of these surgeries are performed each year, making for a $10 billion dollar industry in knee surgery.

The study said that evidence isn't limited to just knee surgeries.

"There's a lot that needs to change when we look at health care in general,"Nolan said. "It's really no surprise that something like doing this regenerative medicine is going to take time for it to really take off."

Read this article:
Danvers health group offers alternative solution to surgery - Wicked Local North of Boston

LMU-DCOM student selected for research project – The Middlesboro Daily News

Courtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

HARROGATE, Tenn. Shannon Strader, a first-year medical student at Lincoln Memorial University-DeBusk College of Osteopathic Medicine, is one of 12 students from across the nation selected to participate in the summer externship program at Shirley Ryan AbilityLab in Chicago.

Strader will spend eight-weeks this summer working in the Department of Physical Medicine and Rehabilitation at Shirley Ryan AbilityLab which has been ranked as the top rehabilitation hospital in America since 1991 by U.S. News and World Report. During the program, students spend two, four-week rotations on separate inpatient rehabilitation services and have the opportunity to observe and participate in related clinical activities. By the end of the externship, each student is expected to write a research paper and present their project to the extern group and invited departmental faculty.

Since my twin sister, Lauryn, passed away from Cerebral Palsy (CP) I have always wanted to research CP. It is what has inspired me to become a doctor and to be an advocate for families confronting CP, Strader said.

Strader attended the University of WisconsinMadison for her undergraduate studies specifically to do research at James A. Thomson Stem Cell and Regenerative Medicine Center. James A. Thomson is an American developmental biologist known as the father of stem cells for being the first person to derive a human embryonic stem cell.

Naturally, as soon I became a medical student I wanted to apply to externship programs dealing specifically with CP research, Strader said. The Shirley Ryan AbilityLab was my first choice, because they are the top rehabilitation facility in the country. People from all over the world come to the AbilityLab to receive care. Im lucky to learn from the best minds in the field.

The summer externship program is sponsored by the Department of Physical Medicine and Rehabilitation of Northwestern University Medical School. Students from both allopathic and osteopathic accredited medical schools across the United States apply for the program. Additionally, each student selected is awarded a $3,000 stipend for participating in the program.

The Shirley Ryan AbilityLab, formerly the Rehabilitation Institute of Chicago (RIC), is the global leader in physical medicine and rehabilitation for adults and children with the most severe, complex conditions from traumatic brain and spinal cord injury to stroke, amputation and cancer-related impairment. The Shirley Ryan AbilityLab expands and accelerates leadership in the field that began at RIC in 1953 its care and research designated the No. 1 Rehabilitation Hospital in America by U.S. News & World Report every year since 1991. Upon opening in March 2017, the $550 million, 1.2-million-square-foot Shirley Ryan AbilityLab became the first-ever translational research hospital in which clinicians, scientists, innovators and technologists work together in the same space, surrounding patients, discovering new approaches and applying (or translating) research real time. Applied research focuses particularly in the areas of neuroscience, bionic medicine, musculoskeletal medicine and technology transfer. This unique model enables patients to have 24/7 access to the brightest minds, the latest research and the best opportunity for recovery. For more information, go to http://www.sralab.org.

Courtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

http://www.middlesborodailynews.com/wp-content/uploads/2017/07/web1_shannon-strader-web.jpgCourtesy of LMU Shannon Strader, an osteopathic medical student at LMU-DCOM poses in front of the Shirley Ryan Ability Lab in Chicago.

.

Read the original post:
LMU-DCOM student selected for research project - The Middlesboro Daily News

Siberian scientists say stem cells can treat varicose veins – Russia Beyond the Headlines

Scientists at the Institute of Chemical Biology and Fundamental Medicine (ICBFM) based in Siberia have discovered that stem cells can restore blood flow in veins with clots.

Facebook

Pinterest

WhatsApp

"Quite a lot of pathologies regarding veins still remain unstudied." Source: Getty Images

To help treat varicose veins, scientists need to accelerate the growth of blood vessels, which would be a crucial development for cardiac medicine. A heart attack is caused by damaged arteries, and an ischemic stroke also often results from vascular damage.

"Quite a lot of pathologies regarding veins still remain unstudied," said Igor Mayborodin, a doctor of medical sciences at the stem cell laboratory at ICBFM. "Weve looked into blood flow restoration in situations when there are blood clots. Now were trying to use stem cells to stimulate the growth of veins and bypass the diseased area."

The discovery by Siberian scientists will make it possible to successfully treat diseases of the veins and resulting complications, for example, varicosis, phlebothrombosis (the formation of a blood clot in the vein that leads to its blockage), and even some types of trophic ulcers and cerebral strokes.

Researchers conducted a number of studies on rats, injecting them with stem cells taken from their relatives. The experiment showed that within a week small vessels had formed in the rodents, and in the third week the replacement of the introduced cells with the rodents' own cells began.

The new blood vessels remained in the body but stem cells that formed walls were gradually replaced by those of the rodents. Thus, scientists showed that stem cells can restore blood flow, bypassing damaged veins. Based on the results, a series of articles will be prepared.

Also, scientists witnessed unexpected side effects. "Some of the stem cells die, and then macrophages are attracted to the site, that is, 'ingester' cells capable of actively engulfing and digesting the remains of dead cells," Mayborodin said. "This is what helps a surgical wound be rid of damaged tissue quicker and heal. This is a good result."

The scientists are continuing their state-funded research, and they have obtained a patent for their work. For the time being, however, they cant check the results in clinical tests because Russian law restricts the use of stem cells on humans.

"Wed like to utilize the obtained data in regards to humans, but this is currently not possible," Mayborodin said. "For now were refining the results of the research on cell therapy and clarifying possible complications. But wed like to test our hypothesis at least on a severe case of varicosis in clinical conditions."

Read more:
Siberian scientists say stem cells can treat varicose veins - Russia Beyond the Headlines

Stemcell Stroke hold the key to changing the face of medicine forever. – Checkbiotech.org (press release)

Stem Cell Testomonials

Billions of dollars are being spent at it very rapid pace over the last 10 years trying to get regulatory approval and or something to patent in order to make profit.

But if you look at Stemcell Stroke logically from a non-medical point of View I think as a consumer logic oftentimes outweighs government oversight

God created stem cells as an agent to build and develop of the human body and it is Americal in itself how the process works so why are we counting on the government to tell us its a potential medical miracle when its already a miracle on its own

Its a proven fact that a child grows in approximately nine months between six and 10 pounds but at birth when the Whartons jelly is pushed into the baby system over the next nine months they will grow 3 to 5 times faster logic would say that those stem cells are doing their job and multiplying at a rapid rate as designed by God

Other scientific proof to validate what God already knows is that the older you get the few were stem cells you have in your body, multiplied by the fact if you take Staten drugs as you age for different things they will actually kill out Stemcell Stroke giving you a smaller stem cell count so why in the world would you extract Stemcell Stroke the 40-year-old body and put them back into you thinking that its going to give you the same results as brand-new stem cells from a newborn?

Another known fact that just makes you think about logic and Houston cells work but as you age your ability to heal a cut is slower than when youre young When youre young and get a cut you heal very quickly but if youre 60 or 70 or 80 you heal slower and that is a process that happens because of the workers themselves in your body making you think logically the older you get the few were Stemcell Stroke have thats why it takes longer for a cut to heal.

So being a logical person those things very much intrigued me but I still had questions before I had some foreign object injected into my body so I started asking around and that is when I really became a believer.

I spoke to her mother who had a teenage son injured in a lacrosse accident and was desperate for pain relief She had an MRI done showing a tear in vertebrae and post Stemcell Stroke shins the MRI showed that there was healing just within 30 days and the childs pain was gone.

I spoke to an older gentleman who had stem cells injected through an IV and he said within 60 days he noticed a change in mobility as well as facial changes that were a positive after having a stroke He had done Rehab on his arm and leg and was not happy with the results and after 60 days post stem cell he was 50% better than before and believes its only going to get better over time. His provider said at six months he may want to take another round if he does not get the full effect that hes looking for, but he is very happy already

Doing my research I found a provider who has been doing stem cell injections on his daughter who has down syndrome and not only has he noticed a difference but the private school that she goes to called him out of the blue one day letting him know that his daughter is doing cognitively better. This was 8 on warranted call but they thought the change was so significant that they should notify or at least have a conversation with the family

A lady I I go to church with told me with some embarrassment that she had stem cell injections, but when she found out I was investigating them she was more than happy to tell me her success story

She plays tennis through high school and college and as she aged she started having pain in her knee and buy Christmas of last year she had to stop playing tennis completely and it was very sad and desperate to get back on the court so she got a stem cell injection in both of her knees and after six weeks she was back to playing tennis or the five hours a week. That was over a year ago and shes been actually playing better than she has in her 40s and 30s thanks to Stemcell injections in her knee.

During my research process, I actually met a gentleman who could not even hold a cuppa coffee in his hand and could barely open his hands because of osteoarthritis wanting to know how it worked out I asked him if it was OK if I followed up with him in 60 days At the 3 to 4 weeks. He actually called me to let me know that hes now able to actually not only hold a coffee cup but you can actually right and sign his name but she has not been able to do for years.

The process was actually quite simple, after meeting with my provider and choosing a 1 mL injection going into the office, filling out the paperwork was probably the longest part of the process once in the procedure room it took less than five minutes and I really back did you work within just a couple hours.

I actually noticed a difference within about three days, and my original pain and inflammation I believe went down as well

A surprise happened I actually also had a pain in my left shoulder but it was not worth spending the money on getting an injection for however, I do believe that the stem cells have traveled across my body to my shoulder and have actually made a difference there as well

Another surprise is I believe, and Im not sure how to test but I do feel like I am able to remember and have maybe more mental clarity for lack of better words not sure the medical words or terms but its crazy what the stem cells have the ability to help

Im not a doctor, nor our stem cells the magic bullet but I believe after my experience that there may be some logic to having injections maybe once a year or every other year to help my body do what God designed it to do.

Overall as a consumer the risks at this point were away outweighed by the reward and success of my stem cell injection and I would just advise anybody to think about the government approval and the FDA process and what its going to take for them to approve something thats not a drug, which is completely natural And wait for them to say yes youre able to do this to your body Illogic person such as myself may believe that I have the choice and I am willing to take the risk to make myself or my life better and that should not be regulated by the government and give Stemcell Injections a try

I do believe you are the captain of your body, and you should choose how youre going to take care of it and not count on only doctors and the government to tell you how to make yourself well again so use your logic and make the choice right for you

Read more from the original source:
Stemcell Stroke hold the key to changing the face of medicine forever. - Checkbiotech.org (press release)